AD
ADTX.US Aditxt Inc.
- Market cap
- USD 399K
- P/E
- -
- P/B
- 0.05x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is ADTX.US undervalued?
Graham numberThe Graham number of Aditxt Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aditxt Inc. fundamental analysis
No fundamental analysis for Aditxt Inc. yet.
Aditxt Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aditxt Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, …
Full company profileAditxt Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aditxt Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 105K | 934K | 645K | 134K | 3.20K | 48.6K |
| Gross Profit | - | - | - | -17.8K | 27.1K | 167K | -112K | -493K | 268.00 | 11.5K |
| Operating Income | -213K | -5.61M | -5.87M | -8.87M | -41.9M | -25.5M | -26.1M | -27.9M | -19.6M | -17.4M |
| EBITDA | 639K | -5.61M | -5.87M | -8.82M | -44.0M | -24.8M | -25.5M | -27.0M | -40.1M | -64.4M |
| Net Income | -213K | -5.69M | -5.83M | -9.15M | -46.4M | -27.7M | -32.4M | -34.4M | -41.7M | -63.8M |
| EPS | - | - | - | -1.33 | -4,637,100,000 | -691,250,000 | -3,026,247 | -295,395 | -1,117 | -3,162 |
| Balance Sheet | ||||||||||
| Total Assets | 25.0K | 116K | 124K | 13.1M | 16.7M | 10.7M | 44.6M | 32.1M | 16.5M | 13.9M |
| Total Liabilities | 84.9K | 1.65M | 2.98M | 2.09M | 6.48M | 5.53M | 28.5M | 23.9M | 12.6M | 49.1M |
| Shareholders' Equity | -59.9K | -1.54M | -2.85M | 11.0M | 10.2M | 5.21M | 16.0M | 8.29M | 5.61M | -33.3M |
| Cash & Short-term Investments | 25.0K | 116K | 4.09K | 10.5M | 7.87M | 2.77M | 97.1K | 833M | 3.20M | 269K |
| Total Debt | - | 164K | 166K | 1.84M | 4.72M | 3.38M | 18.2M | 6.92M | 3.01M | 4.23M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -386K | -386K | -464K | -7.22M | -22.3M | -22.4M | -18.6M | -16.8M | -25.7B | -18.3M |
| Capital Expenditure | 171K | 171K | 171K | 171K | 1.02M | 367K | 14.4K | 1.00 | 13.7M | 41.5K |
| Free Cash Flow | - | -386K | -464K | -7.39M | -23.3M | -22.8M | -18.6M | -16.8M | -25.7B | -18.4M |
| Ratios | ||||||||||
| ROE | - | - | - | -83.1% | -455.5% | -531.1% | -201.8% | -415.7% | -743.6% | - |
| ROA | -852.0% | -4,916.8% | -4,719.1% | -69.9% | -278.3% | -257.6% | -72.6% | -107.2% | -252.6% | -458.7% |
| Net Profit Margin | - | - | - | - | -44,148.6% | -2,961.3% | -5,018.9% | -25,708.8% | -1,305,608.8% | -131,159.8% |
| Debt to Equity | - | - | - | 0.17x | 0.46x | 0.65x | 1.14x | 0.84x | 0.54x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aditxt Inc. dividends
Aditxt Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:27 on May 18, 2026.
Who owns Aditxt Inc.
- Insiders 0.41%
- Institutions 0.46%
- Public & others 99.13%
- Shares outstanding 998M
- Free float 815K
Top funds holding ADTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 435.00 | 0.00% | +0.23% | May 2026 |
Top institutions holding ADTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 11.7K | 0.00% | 0.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 8.00K | 0.00% | 0.00% | Mar 2026 |
| Group One Trading, LLC | 2.00 | 0.00% | 0.00% | Mar 2026 |
| IFP Advisors, LLC | 2.00 | 0.00% | 0.00% | Mar 2026 |
| Western Wealth Management, LLC | 1.00 | 0.00% | 0.00% | Mar 2026 |
| UBS Group AG | 1.00 | 0.00% | 0.00% | Mar 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| FMR Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| FLOW TRADERS U.S. LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Danske Bank A/S. | 0.00 | 0.00% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
Aditxt Inc. company profile
- Company name
- Aditxt Inc.
- Ticker
- ADTX.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Fiscal year end
- December
- Address
- 2569 Wyandotte Street, Mountain View, CA, United States, 94043
- Phone
- 650 870 1200
- Website
- aditxt.com
About Aditxt Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Aditxt Inc. management
3- Ms. Corinne D. Pankovcin CPA, M.B.A.Chief Mergers & Acquisitions Officer · born 1966
- Mr. Jeffrey M. Busch J.D.Chief Executive Officer · born 1960
- Ms. Jennifer LeeVice-President of Human Resources & Talent Acquisition